Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

• DOI: 10.1200/jco.21.01375
• Publication Date: 2021-12-06T20:59:31Z
• Authors: Wayne L. Furman; Beth McCarville; Barry L. Shulkin; Andrew Davidoff; Matthew Krasin; Chia-Wei Hsu; Haitao Pan; Jianrong Wu; Rachel Brennan; Michael W. Bishop; Sara Helmig; Elizabeth Stewart; Fariba Navid; Brandon Triplett; Victor Santana; Teresa Santiago; Jacquelyn A. Hank; Stephen D. Gillies; Alice Yu; Paul M. Sondel; Wing H. Leung; Alberto Pappo; Sara M. Federico
• Keywords: Chemoimmunotherapy; Regimen; Induction chemotherapy; Melphalan

We evaluated whether combining a humanized antidisialoganglioside monoclonal antibody (hu14.18K322A) throughout therapy improves early response and outcomes in children with newly diagnosed high-risk neuroblastoma.